Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe is a synthetic thrombin receptor agonist peptide.
Trp-Lys-Tyr-Met-Val-Met-NH2 (WKYMVm) is a synthetic peptide that is also a specific agonist for formyl peptide-like receptor 1 (FPRL1).
Trpm4-in-1 (CBA) is an effective and selective cationic channel TRPM4 inhibitor with an IC50 of 1.5 μM.
Trpm4-in-1 (CBA) is an effective and selective cationic channel TRPM4 inhibitor with an IC50 of 1.5 μM.
TRULI inhibits Lats1 and Lats2 with IC50 of 0.2 nM, inhibits Yap phosphorylation, induces cell proliferation of multiple cell lines and tissues, and promotes the initial stage of proliferation and regeneration of sensory receptors in the inner ear.
TRULI inhibits Lats1 and Lats2 with IC50 of 0.2 nM, inhibits Yap phosphorylation, induces cell proliferation of multiple cell lines and tissues, and promotes the initial stage of proliferation and regeneration of sensory receptors in the inner ear.
TRULI inhibits Lats1 and Lats2 with IC50 of 0.2 nM, inhibits Yap phosphorylation, induces cell proliferation of multiple cell lines and tissues, and promotes the initial stage of proliferation and regeneration of sensory receptors in the inner ear.
TRULI inhibits Lats1 and Lats2 with IC50 of 0.2 nM, inhibits Yap phosphorylation, induces cell proliferation of multiple cell lines and tissues, and promotes the initial stage of proliferation and regeneration of sensory receptors in the inner ear.
TRULI inhibits Lats1 and Lats2 with IC50 of 0.2 nM, inhibits Yap phosphorylation, induces cell proliferation of multiple cell lines and tissues, and promotes the initial stage of proliferation and regeneration of sensory receptors in the inner ear.
TRV-120027 (also known as TRV027) is an angiotensin II receptor type 1 (AT1R) antagonist and engages ß-arrestins while blocking G-protein signaling.
TRV-120027 (also known as TRV027) is an angiotensin II receptor type 1 (AT1R) antagonist and engages ß-arrestins while blocking G-protein signaling.
TRV-120027 (also known as TRV027) is an angiotensin II receptor type 1 (AT1R) antagonist and engages ß-arrestins while blocking G-protein signaling.